# EDGAR Filing Document

**Accession Number:** 0001694665
**File Stem:** 0001062993-23-004101
**Filing Date:** 2023-2
**Character Count:** 9448
**Document Hash:** 952771985bcfb589b842b19b9b2c57c7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-23-004101.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0001062993-23-004101

**CONFORMED SUBMISSION TYPE**: SC 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230221

**DATE AS OF CHANGE**: 20230221

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evelo Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001694665
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 465594527
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90477
- **FILM NUMBER:** 23645127

**BUSINESS ADDRESS:**
- **STREET 1:** 620 MEMORIAL DRIVE SUITE 500
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617-577-0300

**MAIL ADDRESS:**
- **STREET 1:** 620 MEMORIAL DRIVE SUITE 500
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DNCA FINANCE
- **CENTRAL INDEX KEY:** 0001752759
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 19 PLACE VENDOME
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75001
- **BUSINESS PHONE:** 158625500

**MAIL ADDRESS:**
- **STREET 1:** 19 PLACE VENDOME
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75001

------

**UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**

**SCHEDULE 13D**<br>

Under the Securities Exchange Act of 1934 (Amendment No. 3)

<u>**EVELO BIOSCIENCES, INC.**</u>

(Name of Issuer) <br>

<u>**Common Shares**</u>

(Title of Class of Securities) <br>

<u>**299734103**</u>

(CUSIP Number) <br>

**DNCA FINANCE S.C.S** <br>**19, Place Vendôme 75001 Paris, FRANCE**

<u>**To : Mr. Rodrigo LOZANO<br>**</u><br> (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

<u>**February 15<sup>th</sup> ,2023**</u>

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ].

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b) for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

**SCHEDULE 13D**

---

| | |
|:---|:---|
| &nbsp;&nbsp; **CUSIP No.** | &nbsp;&nbsp; 299734103 |

---

---

| | | |
|:---|:---|:---|
| **1** | NAMES OF REPORTING PERSONS<br>I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | NAMES OF REPORTING PERSONS<br>I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| **1** | DNCA FINANCE S.C.S | DNCA FINANCE S.C.S |
| **2** | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* |
| **2** | &nbsp;&nbsp;&nbsp;&nbsp;(a) [ ]<br>(b) [ ] | &nbsp;&nbsp;&nbsp;&nbsp;(a) [ ]<br>(b) [ ] |
| **3** | SEC USE ONLY | SEC USE ONLY |
| **3** |  |  |
| **4** | SOURCE OF FUNDS (See Instructions) | SOURCE OF FUNDS (See Instructions) |
| **4** | WC | WC |
| **5** | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) |
| **5** | [ ] | [ ] |
| **6** | CITIZENSHIP OR PLACE OF ORGANIZATION | CITIZENSHIP OR PLACE OF ORGANIZATION |
| **6** | PARIS, FRANCE | PARIS, FRANCE |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | **7** | SOLE VOTING POWER |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | **7** | 5 376 445 |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | **8** | SHARED VOTING POWER |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | **8** | 0 |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | **9** | SOLE DISPOSITIVE POWER |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | **9** | 5 376 445 |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | **10** | SHARED DISPOSITIVE POWER |
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | **10** | 0 |
| **11** | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| **11** | 5 376 445 | 5 376 445 |
| **12** | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) |
| **12** | [ ] | [ ] |
| **13** | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) |
| **13** | 4.96% | 4.96% |
| **14** | TYPE OF REPORTING PERSON (See Instructions) | TYPE OF REPORTING PERSON (See Instructions) |
| **14** | IV | IV |

---

------

**Item 1. Security and Issuer**

This statement on Schedule 13D (this "Schedule 13D") relates to the common shares ("**The Securities**"), of EVELO BIOSCIENCES, INC. (the "**Issuer**") which is located at 620 Memorial Drive, 5<sup>th</sup> Floor Cambridge, MA, 02139 USA.

**Item 2. Identity and Background**

This Schedule 13D which is being filed pursuant to Regulation 13D-2 of the General Rules and Regulations under Securities Exchange Act of 1934 as amended (The "**Act**") by DNCA Finance S.C.S. a French asset management company ("**DNCA**") acting in the name of its managed fund DNCA Invest, an umbrella structured fund incorporated under the laws of the Grand Duchy of Luxembourg registered with the Trade and Company Register of Luxembourg under B 125012 and located at 60 avenue J.F. Kennedy L-1855 Luxembourg , Grand Duchy of Luxembourg ("**DNCA Invest**"). DNCA is controlled as defined in article L. 233-9 II of the French Commercial Code and articles 223-12 and 223-12-1 of the General regulations of the *Autorité des Marchés Financiers* (French Financial Authority) by the public limited company Natixis Investment Managers ("**the Parent Company**"). DNCA declares that it acts independently of its Parent Company and is duly empowered to act in the name of the investments funds it manages. (The "**Reporting Persons**").

The principal business of the Reporting Persons is the management of portfolios on behalf of any natural or legal person and the receipt and transmission of orders on behalf of any third party.

**Item 3. Source and Amount of Funds or Other Considerations**

The Securities described in the present Schedule 13D Form were sold by the Reporting Persons on February 15<sup>th</sup>, 2023, following a sell order of 52 323 shares at USD 0.803. The resulting funds were collected by DNCA Invest - Beyond Global Leaders a sub-fund of the DNCA Invest (the "**Sub-fund**").

**Item 4. Purpose of Transaction**

The transaction was made within the context of the Sub-fund's investment strategy which can be consulted on DNCA Invest's prospectus in effect in DNCA's website: <u>https://www.dnca-investments.com</u>/

**Item 5. Interest in Securities of the Issuer**

As of the present schedule date, the Reporting Persons holds 5 376 445 common shares which represent 4.96% of the issued and outstanding shares.

**Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer**

N/A

**Item 7. Material to Be Filed as Exhibits**

------

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| |
|:---|
| February 17<sup>th</sup>, 2023 |
| Dated |
| /s/ Eric FRANC |
| Signature |
| Eric FRANC, CEO |
| Name/Title |

---

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

**Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).**

------